SH5 Stock Overview
Engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Sotera Health Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.30 |
| 52 Week High | US$15.90 |
| 52 Week Low | US$9.90 |
| Beta | 2.08 |
| 11 Month Change | 2.14% |
| 3 Month Change | 7.52% |
| 1 Year Change | 17.21% |
| 33 Year Change | -31.77% |
| 5 Year Change | n/a |
| Change since IPO | -38.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| SH5 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -0.7% | 1.3% | 1.1% |
| 1Y | 17.2% | 11.7% | 12.5% |
Return vs Industry: SH5 exceeded the German Life Sciences industry which returned 12% over the past year.
Return vs Market: SH5 exceeded the German Market which returned 11.8% over the past year.
Price Volatility
| SH5 volatility | |
|---|---|
| SH5 Average Weekly Movement | 4.8% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SH5 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: SH5's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3,000 | Michael Petras | soterahealth.com |
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.
Sotera Health Company Fundamentals Summary
| SH5 fundamental statistics | |
|---|---|
| Market cap | €4.23b |
| Earnings (TTM) | €65.29m |
| Revenue (TTM) | €1.04b |
63.6x
P/E Ratio4.0x
P/S RatioIs SH5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SH5 income statement (TTM) | |
|---|---|
| Revenue | US$1.12b |
| Cost of Revenue | US$502.46m |
| Gross Profit | US$618.01m |
| Other Expenses | US$547.52m |
| Earnings | US$70.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.25 |
| Gross Margin | 55.16% |
| Net Profit Margin | 6.29% |
| Debt/Equity Ratio | 473.4% |
How did SH5 perform over the long term?
See historical performance and comparison